Skip to Main Content

Paper Details

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
5
2022
Author NameAffiliation
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Qingyi WeiThe University of Texas MD Anderson Cancer Center
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Rashmi Kanagal-ShamannaThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2